FDA Clearance Tracker · P130029-S002
FLUENCY PLUS ENDOVASCULAR STENT GRAFT
Last checked: Nov 20, 2026Latest source record: Apr 26, 2016 (this decision)Source: openFDAMethods & limitations
Decided
Apr 26, 2016
Approved
Time to decision
361 days
Received May 1, 2015. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Panel Track
Device class
Class III
The decision
- FDA number
- P130029-S002
- Device name
- FLUENCY PLUS ENDOVASCULAR STENT GRAFT
- Applicant
- Bard Peripheral Vascular, Inc.
- Applicant location
- Tempe, AZ
- Received
- May 1, 2015
- Decided
- Apr 26, 2016
- Decision
- Approved
- Supplement type
- Panel Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P130029
Device type
- Device type
- System, endovascular graft, arteriovenous (AV) dialysis access circuit stenosis treatment (PFV)
- Device class
- Class III
- Specialty
- CardiologyInterventional Cardiology
FDA's approval statement
As written in FDA's record.
Approval for the Fluency Plus Endovascular Stent Graft. This device is indicated for use in the treatment of in-stent restenosis in the venous outflow of hemodialysis patients dialyzing by either an arteriovenous (AV) fistula or AV graft and for the treatment of stenosis in the venous outflow of hemodialysis patients dialyzing by an AV graft.
Source documents
Other decisions for Bard Peripheral Vascular, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P250050 · Decided Sep 25, 2026 · 303 days after receipt
Device type: SHUNT, PORTOSYSTEMIC, ENDOPROSTHESIS (MIR) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.